Drospirenone/estetrol
Pharmaceutical combination
From Wikipedia, the free encyclopedia
Drospirenone/estetrol, sold under the brand name Nextstellis, among others, is a fixed-dose combination medication containing drospirenone, a progestin, and estetrol, an estrogen, which is used as a combined birth control pill for the prevention of pregnancy in women.[2][6] It is taken by mouth.[2][6]
| Combination of | |
|---|---|
| Drospirenone | Progestogen |
| Estetrol (medication) | Estrogen |
| Clinical data | |
| Trade names | Nextstellis, Drovelis, Lydisilka, others |
| Other names | E4/DRSP; FSN-013 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| ChemSpider |
|
| KEGG | |
It was approved for medical use in Canada in March 2021,[3] and in the United States in April 2021.[6]
Medical uses
Drospirenone/estetrol is used as a combined birth control pill to prevent pregnancy in women.[2][6]
Side effects
Estetrol-containing birth control pills, similarly to estradiol-containing birth control pills, may have a lower risk of venous thromboembolism (VTE) than ethinylestradiol-containing birth control pills based on studies of coagulation.[11][12] However, it is likely that another decade will be required before post-marketing epidemiological studies of VTE incidence with these birth control pills are completed and able to confirm this.[13]
Pharmacology
Pharmacodynamics
Drospirenone/estetrol has a much lower impact on liver protein synthesis, including of sex hormone-binding globulin, angiotensinogen, and coagulation factors, than does ethinylestradiol/drospirenone.[14]
